Prognostic value of cardiac biomarkers and Phoenix criteria in pediatric sepsis: a retrospective cohort study

Basit Öğe Kaydı
dc.contributor.authorIpek, Sevcan
dc.contributor.authorGullu, Ufuk Utku
dc.contributor.authorGungor, Sukru
dc.contributor.authorGullu, Seyma Demiray
dc.date.accessioned2026-04-04T13:33:09Z
dc.date.available2026-04-04T13:33:09Z
dc.date.issued2025
dc.departmentİnönü Üniversitesi
dc.description.abstractBackgroundThis study investigated the effects of cardiac biomarkers at admission on the prognosis and timing of vasoactive drug administration in children with sepsis according to the 2005 SIRS criteria. Additionally, the Phoenix sepsis criteria have been applied to patients and examined in detail.MethodsThe study was conducted as a single-center retrospective study between March 2019 and 2022. Laboratory parameters and echocardiographic measurements at admission were evaluated. The primary outcomes are mortality and vasoactive drug use. Receiver operating characteristic (ROC) analysis was used to determine the time to initiate vasoactive drugs.ResultsIn this study 162 (45.1% females) children with sepsis were included. The total mortality was 26.4%. Among the 162 patients, 28.6% were not classified as having sepsis according to the Phoenix 4 criteria and 24.2% according to the Phoenix 8 criteria. Among the non-surviving patients, 9.3% were not classified as sepsis according to the Phoenix 4 criteria (p = 0.001) and 7% according to the Phoenix 8 criteria (p = 0.002). ROC analysis revealed that a pro-BNP value of >= 1835 ng/L predicted the initiation of vasoactive therapy with 73.1% sensitivity and 90.9% specificity (p = 0.002).ConclusionsLaboratory parameters such as pro-BNP obtained in the early stages of the disease could serve as good guides for in determining the timing of initiation of vasoactive drug therapy. Furthermore, the fact that children who died did not meet the Phoenix sepsis criteria raises concerns about the ability of these criteria to detect sepsis at an early stage.
dc.identifier.doi10.1186/s12887-025-06374-1
dc.identifier.issn1471-2431
dc.identifier.issue1
dc.identifier.orcid0000-0002-5561-3598
dc.identifier.orcid0000-0003-3596-2704
dc.identifier.pmid41272557
dc.identifier.scopus2-s2.0-105026153059
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1186/s12887-025-06374-1
dc.identifier.urihttps://hdl.handle.net/11616/108968
dc.identifier.volume25
dc.identifier.wosWOS:001650834900001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherBmc
dc.relation.ispartofBmc Pediatrics
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250329
dc.subjectAdrenaline
dc.subjectDobutamine
dc.subjectNoradrenaline
dc.subjectPediatric complex chronic condition
dc.subjectPediatric sepsis
dc.subjectPhoenix sepsis criteria
dc.subjectPro-BNP
dc.titlePrognostic value of cardiac biomarkers and Phoenix criteria in pediatric sepsis: a retrospective cohort study
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu